Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.

Diabetic medicine : a journal of the British Diabetic Association - 1 Oct 2012

Axelsson S, Hjorth M, Ludvigsson J, Casas R

Abstract excerpt

AIM: The balance between T helper cell subsets is an important regulator of the immune system and is often examined after immune therapies. We aimed to study the immunomodulatory effect of glutamic acid decarboxylase (GAD) 65 formulated with aluminium hydroxide (GAD-alum) in children with Type 1 diabetes, focusing on chemokines and their receptors. METHODS: Blood samples were collected from 70 children with Type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD4-Positive T-Lymphocytes
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Glutamate Decarboxylase

Share to Immunologic Memory

Share to Receptors, CCR5

Share to Sweden

Share to T-Lymphocytes, Cytotoxic

Share to Th1 Cells

Source

Identifiers

PMID: 22587593
DOI: 10.1111/j.1464-5491.2012.03710.x

Genes

CCR5
CCL2
CCR4
CCL3
CCL4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.PMID 22587593Read ↗

Efficacy and Safety of GAD- alum Immunotherapy in recent onset Type-1 diabetes: A systematic review and meta-analysisSemantic proximity Read ↗

Efficacy of GAD-alum immunotherapy associated with HLA-DR3-DQ2 in recently diagnosed type 1 diabetesSemantic proximity Read ↗

Serum titres of anti-glutamic acid decarboxylase-65 and anti-IA-2 autoantibodies are associated with different immunoregulatory milieu in newly diagnosed type 1 diabetes patients.Semantic proximity Read ↗

Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.Semantic proximity Read ↗

Immunomodulatory Dual-Sized Microparticle System Conditions Human Antigen Presenting Cells Into a Tolerogenic Phenotype In Vitro and Inhibits Type 1 Diabetes-Specific Autoreactive T Cell Responses.Semantic proximity Read ↗

Similarities between bacterial GAD and human GAD65: Implications in gut mediated autoimmune type 1 diabetesSemantic proximity Read ↗

Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.Semantic proximity Read ↗

Elevated serum cystatin C and IP-10 levels are associated with the pathophysiology and development of generalized anxiety disorder patients: A case-control studySemantic proximity Read ↗

Early epitope- and isotype-specific humoral immune responses to GAD65 in young children with genetic susceptibility to type 1 diabetes.Semantic proximity Read ↗

Dopamine up-regulates Th17 phenotype from individuals with generalized anxiety disorder.Semantic proximity Read ↗

High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes.Semantic proximity Read ↗

Enhanced Th17 phenotype in individuals with generalized anxiety disorder.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.